Cargando…
Bisphosphonate conjugation for bone specific drug targeting
Bones provide essential functions and are sites of unique biochemistry and specialized cells, but can also be sites of disease. The treatment of bone disorders and neoplasia has presented difficulties in the past, and improved delivery of drugs to bone remains an important goal for achieving effecti...
Autores principales: | Farrell, Kristen B., Karpeisky, Alexander, Thamm, Douglas H., Zinnen, Shawn |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6037665/ https://www.ncbi.nlm.nih.gov/pubmed/29992180 http://dx.doi.org/10.1016/j.bonr.2018.06.007 |
Ejemplares similares
-
First‐in‐Human Phase I Study of MBC‐11, a Novel Bone‐Targeted Cytarabine‐Etidronate Conjugate in Patients with Cancer‐Induced Bone Disease
por: Zinnen, Shawn Patrick, et al.
Publicado: (2018) -
Inhibition of Osteoclast Differentiation and Bone Resorption by Bisphosphonate-conjugated Gold Nanoparticles
por: Lee, Donghyun, et al.
Publicado: (2016) -
Bisphosphonate conjugation enhances the bone-specificity of NELL-1-based systemic therapy for spaceflight-induced bone loss in mice
por: Ha, Pin, et al.
Publicado: (2023) -
Targeting of radioactive platinum-bisphosphonate anticancer drugs to bone of high metabolic activity
por: Nadar, Robin A., et al.
Publicado: (2020) -
Polyethylenimine–Bisphosphonate–Cyclodextrin
Ternary Conjugates: Supramolecular Systems for the Delivery of Antineoplastic
Drugs
por: Plesselova, Simona, et al.
Publicado: (2021)